A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD in relapsed, recurrent ovarian cancer (OC)

Authors
Category Primary study
Year 2009
This article has no abstract
Epistemonikos ID: 4f49216e2de9ce935eb67a2ab2ef9c3d9b55ab83
First added on: May 12, 2020